Related Experiment Video

Updated: Dec 6, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

690

Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma

Chengwei Peng1, Deirdre J Cohen2

  • 1NYU Perlmutter Cancer Center , New York, NY, USA.

Expert Opinion on Pharmacotherapy
|October 9, 2020
PubMed
Abstract

Insights

Esophageal squamous cell carcinoma (ESCC) treatment has advanced with new immunotherapies for metastatic disease. However, novel treatments are still needed as overall prognosis remains poor for this cancer.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Esophageal squamous cell carcinoma (ESCC) is a significant global cause of mortality.
  • Recent approvals of immunotherapy drugs offer new options for metastatic ESCC.

Purpose of the Study:

  • To review the epidemiology and genomics of ESCC.
  • To examine targeted agents, approved immunotherapies, and novel combinations for ESCC treatment.

Main Methods:

  • Literature review of epidemiological and genomic data for ESCC.
  • Analysis of clinical trials involving targeted therapies and immunotherapies.
  • Evaluation of approved immunotherapy drugs and combination strategies.

Main Results:

  • Advances in understanding ESCC molecular changes have been made.
  • Few drugs have demonstrated significant benefit in treating ESCC.
  • Targeted therapies have not improved survival, often lacking biomarker exploration.

Conclusions:

  • Pembrolizumab and nivolumab are approved for metastatic ESCC, but further data are needed for non-metastatic settings.
  • Despite progress, novel treatments are essential as the overall prognosis for ESCC remains poor.
Keywords:
Canceresophageal squamous cell carcinomaimmunotherapytargeted therapy

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.0K
Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

4.1K

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
543
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
289
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
265
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
507
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
291